About the ENGAGE and EMERGE studies
Two identical clinical studies investigating a potential new treatment for early Alzheimer’s disease.
- In brief
- Who we’re looking for
The hallmark of Alzheimer’s disease is the development of plaques (sticky deposits, sometimes called clumps) and tangles of certain types of proteins in the brains. These plaques are made up of a protein called beta-amyloid, which is thought to be a major cause of brain cell death which contributes to the progression of Alzheimer’s disease.
Many researchers think that developing drugs to target beta-amyloid could help to slow or halt the progress of the disease, when taken early.
That’s why we’re conducting the ENGAGE and EMERGE studies – to see how safe and effective an investigational anti-plaque medication is in slowing the progression of early Alzheimer’s disease.
We’re looking for 2,700 participants from around the world to take part.
Key features of the studies
- For men and women 50–85 years old*
- Study medication given by intravenous infusions (a slow injection into a vein)
- 2-in-3 people will receive investigational medication
- 18 months plus. Optional long-term extension study
- A phase 3 study
*Please note that other eligibility criteria apply
If you meet eligibility criteria, you will participate in either ENGAGE or EMERGE, but not both. The only difference between them is the locations in which the trials are being run.
- For men and women
- 50–85 years old
- Those experiencing symptoms that may be related to early Alzheimer’s disease, such as problems with memory or thinking clearly
- Participants need to have someone as a study partner, to accompany them on certain appointments and provide information about their health
People must meet all other study criteria to participate in the ENGAGE Study or the EMERGE Study. A full list of eligibility criteria is available at www.clinicaltrials.gov
If you take part in one of the studies, you will be asked to visit a study clinic so that we can monitor your health and give you the investigational medication. Assessments will vary from visit to visit, but may include:
- Questionnaires and interviews about how you are thinking, how you are able to perform your daily activities, and how you are feeling
- MRI (magnetic resonance imaging) scans, to produce detailed images of the brain
- PET (positron emission tomography) scans to look at amyloid plaques (abnormal deposits) in the brain; everyone will have one PET scan – but only some participants will have more than one
- Measurements of Vital Signs (blood pressure, heart rate, breathing rate, and temperature, etc.)
- Urine tests
- Electrocardiogram (ECG, a test of the electrical activity of the heart)
- Physical examinations
- Blood tests